Stef Meers

1.4k total citations
22 papers, 416 citations indexed

About

Stef Meers is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Stef Meers has authored 22 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 8 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Stef Meers's work include Acute Myeloid Leukemia Research (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). Stef Meers is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Acute Lymphoblastic Leukemia research (4 papers). Stef Meers collaborates with scholars based in Belgium, United States and Switzerland. Stef Meers's co-authors include Gregor Verhoef, Koen Theunissen, Johan Maertens, Katrien Lagrou, Johan Van Eldere, Wouter Meersseman, Eric Verbeken, Philippe Meersseman, Timothy Devos and Daan Dierickx and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Infectious Diseases.

In The Last Decade

Stef Meers

20 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stef Meers Belgium	9	218	175	103	72	61	22	416
Jane Burgess Australia	14	344 1.6×	83 0.5×	102 1.0×	162 2.3×	239 3.9×	21	670
Kees Sintnicolaas Netherlands	12	204 0.9×	42 0.2×	145 1.4×	222 3.1×	31 0.5×	21	512
Anna Chierichini Italy	9	143 0.7×	117 0.7×	101 1.0×	60 0.8×	81 1.3×	16	348
Michal Kouba Czechia	9	113 0.5×	98 0.6×	187 1.8×	170 2.4×	56 0.9×	18	363
Prashant Hiwarkar United Kingdom	12	245 1.1×	102 0.6×	288 2.8×	179 2.5×	189 3.1×	27	607
Xuying Pei China	11	178 0.8×	54 0.3×	138 1.3×	109 1.5×	117 1.9×	26	330
Christianne Yung United States	7	138 0.6×	111 0.6×	40 0.4×	68 0.9×	14 0.2×	8	302
Robert A. Dunstan United States	13	78 0.4×	49 0.3×	268 2.6×	101 1.4×	32 0.5×	22	474
Brad J. Davis United States	8	51 0.2×	132 0.8×	40 0.4×	31 0.4×	97 1.6×	9	306
M. Jurado Spain	8	180 0.8×	181 1.0×	101 1.0×	81 1.1×	42 0.7×	19	364

Countries citing papers authored by Stef Meers

Since Specialization

Citations

This map shows the geographic impact of Stef Meers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stef Meers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stef Meers more than expected).

Fields of papers citing papers by Stef Meers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stef Meers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stef Meers. The network helps show where Stef Meers may publish in the future.

Co-authorship network of co-authors of Stef Meers

This figure shows the co-authorship network connecting the top 25 collaborators of Stef Meers. A scholar is included among the top collaborators of Stef Meers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stef Meers. Stef Meers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meers, Stef, Koen Theunissen, Koen Van Eygen, et al.. (2024). Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives. SHILAP Revista de lepidopterología. 5(5). 1096–1099.

Zeidan, Amer M., Kiyoshi Ando, Odile Beyne Rauzy, et al.. (2023). Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Haematology. 11(1). e38–e50. 36 indexed citations

Meers, Stef, et al.. (2023). Combined Results of Two Cross-Sectional Surveys on the Participation in Clinical Trials and the e-Consent Procedure in the Landscape of Haematology. SHILAP Revista de lepidopterología. 13(6). 1520–1531.

Meers, Stef, Ann De Becker, Kristien Wouters, et al.. (2023). Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study. Cancers. 15(13). 3296–3296. 2 indexed citations

Meers, Stef, et al.. (2022). Brentuximab vedotin induced uveitis. American Journal of Ophthalmology Case Reports. 26. 101440–101440. 7 indexed citations

Janssens, Ann, Zwi Berneman, Fritz Offner, et al.. (2022). Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. SHILAP Revista de lepidopterología. 4(4). 133–143. 5 indexed citations

Zeidan, Amer M., Kiyoshi Ando, Odile Beyne Rauzy, et al.. (2022). Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS). Blood. 140(Supplement 1). 2063–2065. 11 indexed citations

Meers, Stef, Benjamin Bailly, Isabelle Vande Broek, et al.. (2019). Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia – results from a retrospective Belgian registry study. Acta Clinica Belgica. 76(2). 98–105. 3 indexed citations

Devos, Timothy, Stef Meers, Nancy Boeckx, et al.. (2018). Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. European Journal Of Haematology. 101(6). 737–749. 31 indexed citations

10.

Devos, Timothy, Koen Theunissen, Fleur Samantha Benghiat, et al.. (2018). Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry. Blood. 132(Supplement 1). 1744–1744. 3 indexed citations

11.

Meers, Stef, et al.. (2014). Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia. Current Medical Research and Opinion. 31(1). 35–42. 1 indexed citations

12.

Meers, Stef, Dimitri Breems, Michel Delforge, et al.. (2013). MANAGEMENT OF MYELODYSPLASTIC SYNDROMES IN ADULTS: GUIDELINES FROM THE BELGIAN HAEMATOLOGICAL SOCIETY*1 The responsibility of the content of these guidelines lies with the Belgian Haematological Society. The editorial board of the Acta Clinica Belgica is not responsible for eventual weaknesses or lack of evidence of the published document. Acta Clinica Belgica. 68(4). 253–262. 2 indexed citations

13.

Selleslag, Dominik, et al.. (2011). Plerixafor in poor stem cell mobilizers: the belgian compassionate use program. Lirias (KU Leuven). 6 indexed citations

14.

Meers, Stef, et al.. (2010). Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. Journal of Crohn s and Colitis. 4(6). 683–686. 10 indexed citations

15.

Meers, Stef, Katrien Lagrou, Koen Theunissen, et al.. (2010). Myeloablative Conditioning Predisposes Patients forToxoplasma gondiiReactivation after Allogeneic Stem Cell Transplantation. Clinical Infectious Diseases. 50(8). 1127–1134. 53 indexed citations

16.

Dierickx, Daan, Diethard Monbaliu, Evelyne Lerut, et al.. (2010). Thrombotic Microangiopathy Following Intestinal Transplantation: A Single Center Experience. Transplantation Proceedings. 42(1). 79–81. 12 indexed citations

17.

Maertens, Johan, Koen Theunissen, Wouter Meersseman, et al.. (2009). Bronchoalveolar Lavage Fluid Galactomannan for the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Diseases. Clinical Infectious Diseases. 49(11). 1688–1693. 182 indexed citations

18.

Meers, Stef, Peter Vandenberghe, Marc Boogaerts, et al.. (2008). 5-aza-2 '-deoxycytidine can induce differentiation of clonal abnormal progenitor cells from patients with myelodysplastic syndromes without induction of apoptosis. Haematologica. 93. 91–91. 4 indexed citations

19.

Meers, Stef, Ahmad Kasran, Louis Boon, et al.. (2007). Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells. Leukemia. 21(12). 2411–2419. 15 indexed citations

20.

Meers, Stef, Peter Vandenberghe, Marc Boogaerts, Gregor Verhoef, & Michel Delforge. (2007). The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients. Leukemia Research. 32(7). 1026–1035. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact